Cidara Therapeutics, Inc. - Understand $cdtx stock

$CDTX Market Cap: $140.6 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$26.35M

TTM

Gross Margin

87.54%

TTM

Net Earnings

-$123.1M

TTM

Current Assets

$156.8M

Q3 2024

Current Liabilities

$44.34M

Q3 2024

Current Ratio

353.57%

Q3 2024

Total Assets

$162.3M

Q3 2024

Total Liabilities

$46.70M

Q3 2024

Book Value

$115.6M

Q3 2024

Cash

$127.4M

Q3 2024

P/E

-1.142

Nov 29, 2024 EST

Free Cash Flow

-$160.1M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$63.91M	$64.29M	$49.57M	$12.07M	$20.92M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-0.6%	29.69%	310.7%	-42.3%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$63.91M	$64.29M	$49.57M	$12.07M	$20.92M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$1.523M	$0.00						$0.00	$0.00	$1.610M	$0.00
Gross Profit	$62.38M	$64.45M						$0.00	$0.00	-$1.610M	$0.00
Gross Profit Margin	97.62%	100.25%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Selling, General & Admin	$18.33M	$18.49M	$18.74M	$15.90M	$16.24M	$14.14M	$12.90M	$12.74M	$8.840M	$3.310M	$270.0K
YoY Change	-0.83%	-1.36%	17.86%	-2.09%	14.85%	9.61%	1.26%	44.12%	167.07%	1125.93%
% of Gross Profit	29.39%	28.68%
Research & Development	$68.53M	$75.52M	$73.09M	$68.02M	$46.40M	$49.14M	$42.82M	$35.70M	$23.48M	$6.710M	$810.0K
YoY Change	-9.25%	3.33%	7.45%	46.59%	-5.58%	14.76%	19.96%	52.07%	249.85%	728.4%
% of Gross Profit	109.86%	117.18%
Depreciation & Amortization	$118.0K	$143.0K	$189.0K	$290.0K	$330.0K	$520.0K	$670.0K	$730.0K	$460.0K	$180.0K	$0.00
YoY Change	-17.48%	-24.34%	-34.83%	-12.12%	-36.54%	-22.39%	-8.22%	58.7%	155.56%
% of Gross Profit	0.19%	0.22%
Operating Expenses	$86.87M	$94.01M	$91.83M	$83.92M	$62.64M	$63.29M	$55.72M	$48.44M	$32.31M	$11.62M	$810.0K
YoY Change	-7.6%	2.37%	9.43%	33.97%	-1.02%	13.57%	15.04%	49.9%	178.01%	1334.94%
Operating Profit	-$24.48M	-$29.72M	-$42.26M	-$71.85M	-$41.72M	-$63.29M	-$55.72M	-$48.44M	-$32.31M	-$11.62M	-$810.0K
YoY Change	-17.62%	-29.67%	-41.19%	72.2%	-34.07%	13.57%	15.04%	49.9%	178.01%	1334.94%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Interest Expense	$1.995M	$191.0K	-$212.0K	-$262.0K	$221.0K	$629.0K	-$7.000K	$271.0K	$120.0K	-$88.00K	-$100.0K
YoY Change	944.5%	-190.09%	-19.08%	-218.55%	-64.86%	-9085.71%	-102.58%	125.83%	-236.36%	-12.0%
% of Operating Profit
Other Income/Expense, Net	$1.995M	$191.0K	-$212.0K	-$262.0K	$632.0K	$4.269M	-$7.000K	$271.0K	$120.0K	-$271.0K
YoY Change	944.5%	-190.09%	-19.08%	-141.46%	-85.2%	-61085.71%	-102.58%	125.83%	-144.28%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Pretax Income	-$22.49M	-$29.53M	-$42.47M	-$72.11M	-$41.09M	-$59.02M	-$55.73M	-$48.17M	-$32.19M	-$11.89M	-$1.340M
YoY Change	-23.84%	-30.47%	-41.11%	75.49%	-30.38%	5.9%	15.69%	49.64%	170.73%	787.31%
Income Tax	$443.0K	$272.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$22.93M	-$29.80M	-$42.47M	-$72.11M	-$41.09M	-$59.02M	-$55.73M	-$48.17M	-$32.19M	-$11.89M	-$1.340M
YoY Change	-23.05%	-29.83%	-41.11%	75.49%	-30.37%	5.9%	15.7%	49.61%	170.67%	787.61%
Net Earnings / Revenue	-35.88%	-46.35%	-85.67%	-597.44%	-196.42%
Basic Earnings Per Share	-$0.26	-$0.43	-$0.81	-$1.80	-$1.37
Diluted Earnings Per Share	-$0.26	-$0.43	-$0.81	-$1.80	-$1.37	-$2.348M	-$3.185M	-$3.324M	-$2.334M	-$881.4K	-$99.33K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Cash & Short-Term Investments	$35.78M	$32.73M	$59.68M	$35.90M	$50.30M	$74.60M	$75.30M	$104.6M	$107.5M	$22.80M	$200.0K
YoY Change	9.31%	-45.16%	66.24%	-28.63%	-32.57%	-0.93%	-28.01%	-2.7%	371.49%	11300.0%
Cash & Equivalents	$35.78M	$32.73M	$59.68M	$35.90M	$50.30M	$74.60M	$60.80M	$85.40M	$62.60M	$22.80M	$200.0K
Short-Term Investments						$0.00	$14.50M	$19.30M	$45.00M
Other Short-Term Assets	$2.734M	$6.530M	$6.662M	$10.10M	$10.00M	$2.600M	$2.000M	$800.0K	$700.0K	$200.0K	$0.00
YoY Change	-58.13%	-1.98%	-34.04%	1.0%	284.62%	30.0%	150.0%	14.29%	250.0%
Inventory	$6.097M	$0.00
Prepaid Expenses
Receivables	$16.25M	$5.833M	$5.356M	$11.20M	$5.500M	$0.00	$300.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$60.86M	$45.09M	$71.70M	$57.20M	$65.80M	$77.10M	$77.70M	$105.4M	$108.2M	$23.00M	$200.0K
YoY Change	34.95%	-37.11%	25.35%	-13.07%	-14.66%	-0.77%	-26.28%	-2.59%	370.43%	11400.0%
Property, Plant & Equipment	$5.127M	$1.427M	$2.543M	$1.200M	$2.100M	$700.0K	$1.000M	$1.400M	$1.700M	$900.0K	$0.00
YoY Change	259.29%	-43.89%	111.92%	-42.86%	200.0%	-30.0%	-28.57%	-17.65%	88.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.048M	$1.072M	$1.084M	$2.000M	$1.100M	$1.300M	$300.0K	$200.0K	$100.0K	$500.0K	$0.00
YoY Change	-2.24%	-1.11%	-45.8%	81.82%	-15.38%	333.33%	50.0%	100.0%	-80.0%
Total Long-Term Assets	$6.175M	$2.499M	$3.627M	$3.200M	$3.200M	$2.000M	$1.300M	$1.600M	$1.800M	$1.400M	$0.00
YoY Change	147.1%	-31.1%	13.34%	0.0%	60.0%	53.85%	-18.75%	-11.11%	28.57%
Total Assets	$67.03M	$47.59M	$75.33M	$60.40M	$69.00M	$79.10M	$79.00M	$107.0M	$110.0M	$24.40M	$200.0K
YoY Change
Accounts Payable	$3.772M	$1.447M	$1.301M	$4.600M	$1.900M	$2.800M	$2.600M	$2.900M	$3.100M	$1.200M	$0.00
YoY Change	160.68%	11.22%	-71.72%	142.11%	-32.14%	7.69%	-10.34%	-6.45%	158.33%
Accrued Expenses	$38.33M	$13.91M	$16.20M	$13.10M	$8.500M	$6.700M	$6.800M	$6.000M	$2.900M	$2.000M	$100.0K
YoY Change	175.56%	-14.16%	23.7%	54.12%	26.87%	-1.47%	13.33%	106.9%	45.0%	1900.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$218.0K	$0.00	$2.591M	$7.000M	$10.00M	$9.900M	$2.700M
YoY Change		-100.0%	-62.99%	-30.0%	1.01%	266.67%
Total Short-Term Liabilities	$67.42M	$29.97M	$34.02M	$38.60M	$30.20M	$19.90M	$12.10M	$8.900M	$6.000M	$3.200M	$100.0K
YoY Change	124.94%	-11.89%	-11.87%	27.81%	51.76%	64.46%	35.96%	48.33%	87.5%	3100.0%
Long-Term Debt	$575.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$7.200M	$9.800M	$0.00	$0.00	$1.500M
YoY Change						-100.0%	-26.53%			-100.0%
Other Long-Term Liabilities	$7.247M	$20.53M	$19.74M	$11.10M	$900.0K	$100.0K	$0.00	$100.0K	$100.0K	$0.00	$0.00
YoY Change	-64.69%	4.0%	77.79%	1133.33%	800.0%		-100.0%	0.0%
Total Long-Term Liabilities	$7.822M	$20.53M	$19.74M	$11.10M	$900.0K	$100.0K	$7.200M	$9.900M	$100.0K	$0.00	$1.500M
YoY Change	-61.89%	4.0%	77.79%	1133.33%	800.0%	-98.61%	-27.27%	9800.0%		-100.0%
Total Liabilities	$75.24M	$50.50M	$53.75M	$49.70M	$31.10M	$20.00M	$19.30M	$18.80M	$6.100M	$3.200M	$1.600M
YoY Change	49.0%	-6.06%	8.15%	59.81%	55.5%	3.63%	2.66%	208.2%	90.63%	100.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	87.43M shares	69.86M shares
Diluted Shares Outstanding	87.43M shares	69.86M shares	52.45M shares	41.56M shares	29.93M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $140.58 Million

About Cidara Therapeutics, Inc.

Cidara Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 69 full-time employees. The company went IPO on 2015-04-15. Cidara Therapeutics, Inc. is a biotechnology company. The firm is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The firm is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Industry: Biological Products, (No Diagnostic Substances) Peers: Quince Therapeutics, Inc. SELLAS Life Sciences Group, Inc. Galera Therapeutics, Inc. Oncternal Therapeutics, Inc. Scorpius Holdings, Inc. IN8BIO, INC. MUSTANG BIO, INC. Synaptogenix, Inc. Rubius Therapeutics, Inc.